Body composition and inflammation impact in non-small-cell lung cancer patients treated by first-line immunotherapy

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA: Cancer J. Clin. 69(1), 7–34 (2019).
  MedlineGoogle Scholar
• 2. Goldstraw P, Chansky K, Crowley J et al. The IASLC Lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J. Thorac. Oncol. 11(1), 39–51 (2016).
  MedlineGoogle Scholar
• 3. Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373(2), 123–135 (2015).
  Medline CASGoogle Scholar
• 4. Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373(17), 1627–1639 (2015).
  Medline CASGoogle Scholar
• 5. Herbst RS, Baas P, Kim DW et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387(10027), 1540–1550 (2016).
  Medline CASGoogle Scholar
• 6. Rittmeyer A, Barlesi F, Waterkamp D et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a Phase 3, open-label, multicentre randomised controlled trial. Lancet 389(10066), 255–265 (2017).
  MedlineGoogle Scholar
• 7. Reck M, Rodríguez-Abreu D, Robinson AG et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375(19), 1823–1833 (2016). •• This work brought immunotherapy in the first-line treatment of non-small-cell lung cancer.
  Medline CASGoogle Scholar
• 8. Carbone DP, Reck M, Paz-Ares L et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N. Engl. J. Med. 376(25), 2415–2426 (2017).
  Medline CASGoogle Scholar
• 9. Spigel D, de Marinis F, Giaccone G. IMpower110: interim OS analysis of a Phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as 1L treatment (tx) in PD-L1–selected NSCLC. Ann. Oncol. 30(5), v915 (2019).
  Google Scholar
• 10. Burtness B, Harrington KJ, Greil R et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, Phase 3 study. Lancet 394(10212), 1915–1928 (2019).
  Medline CASGoogle Scholar
• 11. Gandhi L, Rodríguez-Abreu D, Gadgeel S et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med. 378(22), 2078–2092 (2018).
  Medline CASGoogle Scholar
• 12. Paz-Ares L, Luft A, Vicente D et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N. Engl. J. Med. 379(21), 2040–2051 (2018).
  Medline CASGoogle Scholar
• 13. West H, McCleod M, Hussein M et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, Phase 3 trial. Lancet Oncol. 20(7), 924–937 (2019).
  Medline CASGoogle Scholar
• 14. Jotte R, Cappuzzo F, Vynnychenko I et al. Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): results from a randomized Phase III trial. J. Thorac. Oncol. 15(8), 1351–1360 (2020).
  Medline CASGoogle Scholar
• 15. Papadimitrakopoulou V, Cobo M, Bordoni R et al. IMpower132: PFS and safety results with 1L atezolizumab+ carboplatin/cisplatin + pemetrexed in stage IV non-squamous NSCLC. J. Thorac. Oncol. 13(Suppl. 10), S332–S333 (2018).
  Google Scholar
• 16. Socinski MA, Jotte RM, Cappuzzo F et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N. Engl. J. Med. 378(24), 2288–2301 (2018).
  Medline CASGoogle Scholar
• 17. Hellmann MD, Paz-Ares L, Bernabe Caro R et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N. Engl. J. Med. 381(21), 2020–2031 (2019).
  Medline CASGoogle Scholar
• 18. Cehreli R, Yavuzsen T, Ates H, Akman T, Ellidokuz H, Oztop I. Can inflammatory and nutritional serum markers predict chemotherapy outcomes and survival in advanced stage nonsmall-cell lung cancer patients? Biomed. Res. Int. 2019, 1648072 (2019).
  MedlineGoogle Scholar
• 19. Baracos VE, Arribas L. Sarcopenic obesity: hidden muscle wasting and its impact for survival and complications of cancer therapy. Ann. Oncol. 29(Suppl. 2), ii1–ii9 (2018).
  CASGoogle Scholar
• 20. Calder PC. Feeding the immune system. Proc. Nutr. Soc. A72(3), 299–309 (2013).
  Google Scholar
• 21. De Rosa V, Di Rella F, Di Giacomo A, Matarese G. Regulatory T cells as suppressors of anti-tumor immunity: role of metabolism. Cytokine Growth Factor Rev. 35, 15–25 (2017).
  MedlineGoogle Scholar
• 22. Dewys WD, Begg C, Lavin PT et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am. J. Med. 69(4), 491–497 (1980).
  Medline CASGoogle Scholar
• 23. Prado CM, Lieffers JR, McCargar LJ et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumors of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 9(7), 629–635 (2008).
  MedlineGoogle Scholar
• 24. Bozzetti F. Forcing the vicious circle: sarcopenia increases toxicity, decreases response to chemotherapy and worsens with chemotherapy. Ann. Oncol. 28(9), 2107–2118 (2017).
  Medline CASGoogle Scholar
• 25. Hilmi M, Jouinot A, Burns R et al. Body composition and sarcopenia: the next-generation of personalized oncology and pharmacology? Pharmacol. Ther. 196, 135–159 (2019).
  Medline CASGoogle Scholar
• 26. Argilés JM, Busquets S, Stemmler B, López-Soriano FJ. Cancer cachexia: understanding the molecular basis. Nat. Rev. Cancer 14(11), 754–762 (2014).
  Medline CASGoogle Scholar
• 27. Bano G, Trevisan C, Carraro S et al. Inflammation and sarcopenia: a systematic review and meta-analysis. Maturitas 96, 10–15 (2017).
  MedlineGoogle Scholar
• 28. Öztürk ZA, Kul S, Türkbeyler İ, Sayıner ZA, Abiyev A. Is increased neutrophil lymphocyte ratio remarking the inflammation in sarcopenia? Exp. Gerontol. 110, 223–229 (2018).
  MedlineGoogle Scholar
• 29. Burney BO, Hayes TG, Smiechowska J et al. Low testosterone levels and increased inflammatory markers in patients with cancer and relationship with cachexia. J. Clin. Endocrinol. Metab. 97(5), E700–9 (2012).
  Medline CASGoogle Scholar
• 30. Takada K, Yoneshima Y, Tanaka K et al. Clinical impact of skeletal muscle area in patients with non-small cell lung cancer treated with anti-PD-1 inhibitors. J. Cancer Res. Clin. Oncol. 146(5), 1217–1225 (2020).
  Medline CASGoogle Scholar
• 31. Cortellini A, Verna L, Porzio G et al. Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non-small cell lung cancer patients: a “hypothesis-generator” preliminary report. Thorac. Cancer. 10(2), 347–351 (2019). • One of the first works and one of the rare works on the European population concerning the analysis of body composition, specifically analysis of muscle mass, in cancer patients treated with immunotherapy.
  Medline CASGoogle Scholar
• 32. Magri V, Gottfried T, Di Segni M et al. Correlation of body composition by computerized tomography and metabolic parameters with survival of nivolumab-treated lung cancer patients. Cancer Manag. Res. 11, 8201–8207 (2019).
  Medline CASGoogle Scholar
• 33. Nishioka N, Uchino J, Hirai S et al. Association of sarcopenia with and efficacy of anti-PD-1/PD-L1 therapy in non-small-cell lung cancer. J. Clin. Med. 8(4), 450 (2019).
  CASGoogle Scholar
• 34. Popinat G, Cousse S, Goldfarb L et al. Sub-cutaneous fat mass measured on multislice computed tomography of pretreatment PET/CT is a prognostic factor of stage IV non-small cell lung cancer treated by nivolumab. Oncoimmunology 8(5), e1580128 (2019). • One of the rare work on European population and on the analysis of adipose tissue on cancer patient treated with immunotherapy.
  MedlineGoogle Scholar
• 35. Shiroyama T, Nagatomo I, Koyama S et al. Impact of sarcopenia in patients with advanced non-small cell lung cancer treated with PD-1 inhibitors: A preliminary retrospective study. Sci. Rep. 9(1), 2447 (2019).
  MedlineGoogle Scholar
• 36. Tsukagoshi M, Yokobori T, Yajima T et al. Skeletal muscle mass predicts the outcome of nivolumab treatment for non-small cell lung cancer. Medicine (Baltimore) 99(7), e19059 (2020).
  Medline CASGoogle Scholar
• 37. Martin L, Birdsell L, Macdonald N et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J. Clin. Oncol. 31(12), 1539–1547 (2013).
  MedlineGoogle Scholar
• 38. Fearon K, Strasser F, Anker SD et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 12(5), 489–495 (2011). •• One of the most important works and an international consensus in the definition of cancer cachexia.
  MedlineGoogle Scholar
• 39. Cederholm T, Bosaeus I, Barazzoni R et al. Diagnostic criteria for malnutrition – an ESPEN consensus statement. Clin. Nutr. 34(3), 335–340 (2019).
  Google Scholar
• 40. Kobayashi A, Kaido T, Hamaguchi Y et al. Impact of visceral adiposity as well as sarcopenic factors on outcomes in patients undergoing liver resection for colorectal liver metastases. World J. Surg. 42(4), 1180–1191 (2018).
  MedlineGoogle Scholar
• 41. Doyle SL, Bennett AM, Donohoe CL et al. Establishing computed tomography-defined visceral fat area thresholds for use in obesity-related cancer research. Nutr. Res. 33(3), 171–179 (2013).
  Medline CASGoogle Scholar
• 42. Ebadi M, Martin L, Ghosh S et al. Subcutaneous adiposity is an independent predictor of mortality in cancer patients. Br. J. Cancer 117(1), 148–155 (2017).
  MedlineGoogle Scholar
• 43. Martin L, Senesse P, Gioulbasanis I et al. Diagnostic criteria for the classification of cancer-associated weight loss. J. Clin. Oncol. 33(1), 90–99 (2015).
  MedlineGoogle Scholar
• 44. World Health Organization Europe. Body mass index – BMI (2021). www.euro-who-int/en/health-topics/disease-prevention/nutrition/a-healthy-lifestyle/body-mass-index-bmi
  Google Scholar
• 45. Svaton M, Zemanova M, Skrickova J et al. Chronic inflammation as a potential predictive factor of nivolumab therapy in non-small cell lung cancer. Anticancer Res. 38(12), 6771–6782 (2018).
  Medline CASGoogle Scholar
• 46. Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br. J. Cancer 89(6), 1028–1030 (2003). • This is one of the first studies on the analysis of prognostic scores related to inflammation in advanced cancer patients.
  Medline CASGoogle Scholar
• 47. Proctor MJ, Morrison DS, Talwar D et al. An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumor site: a Glasgow inflammation outcome study. Br. J. Cancer 104(4), 726–734 (2011).
  Medline CASGoogle Scholar
• 48. Simmons CP, Koinis F, Fallon MT et al. Prognosis in advanced lung cancer – a prospective study examining key clinicopathological factors. Lung Cancer 88(3), 304–309 (2015).
  MedlineGoogle Scholar
• 49. Ni XF, Wu J, Ji M et al. Effect of C-reactive protein/albumin ratio on prognosis in advanced non-small-cell lung cancer. Asia Pac. J. Clin. Oncol. 14(6), 402–409 (2018).
  MedlineGoogle Scholar
• 50. Ozyurek BA, Ozdemirel TS, Ozden SB et al. Does advanced lung inflammation index (ALI) have prognostic significance in metastatic non-small cell lung cancer? Clin. Respir. J. 12(6), 2013–2019 (2018).
  Medline CASGoogle Scholar
• 51. Shiroyama T, Suzuki H, Tamiya M et al. Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab-treated patients with advanced non-small cell lung cancer. Cancer Med. 7(1), 13–20 (2018).
  Medline CASGoogle Scholar
• 52. Kim EY, Kim N, Kim YS et al. Prognostic significance of modified advanced lung cancer inflammation index (ALI) in patients with small cell lung cancer comparison with original ALI. PLoS ONE 11(10), e0164056 (2016).
  MedlineGoogle Scholar
• 53. Shoji F, Takeoka H, Kozuma Y et al. Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors. Lung Cancer 136, 45–51 (2019).
  MedlineGoogle Scholar
• 54. Kasymjanova G, MacDonald N, Agulnik JS et al. The predictive value of pre-treatment inflammatory markers in advanced non-small-cell lung cancer. Curr. Oncol. 17(4), 52–58 (2010).
  Medline CASGoogle Scholar
• 55. Liu J, Li S, Zhang S et al. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab. J. Clin. Lab. Anal. 33(8), e22964 (2019).
  Medline CASGoogle Scholar
• 56. Takamori S, Toyokawa G, Shimokawa M et al. A novel prognostic marker in patients with non-small cell lung cancer: musculo-immuno-nutritional score calculated by controlling nutritional status and creatine kinase. J. Thorac. Dis. 11(3), 927–935 (2019).
  MedlineGoogle Scholar
• 57. Shoji F, Miura N, Matsubara T et al. Prognostic significance of immune-nutritional parameters for surgically resected elderly lung cancer patients: a multicentre retrospective study. Interact. Cardiovasc. Thorac. Surg. 26(3), 389–394 (2018).
  MedlineGoogle Scholar
• 58. Mitsiopoulos N, Baumgartner RN, Heymsfield SB, Lyons W, Gallagher D, Ross R. Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J. Appl. Physiol. 85(1), 115–122 (1998).
  Medline CASGoogle Scholar
• 59. Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl. Physiol. Nutr. Metab. 33(5), 997–1006 (2008).
  MedlineGoogle Scholar
• 60. Linee Guida AIOM 2018 MELANOMA (2018). www.aiom.it/wp-content/uploads/2018/11/2018_LG_AIOM_Melanoma.pdf
  Google Scholar
• 61. Motzer RJ, Mazumdar M, Bacik J, Russo P, Berg WJ, Metz EM. Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J. Clin. Oncol. 18(9), 1928–1935 (2000).
  Medline CASGoogle Scholar
• 62. Yang JR, Xu JY, Chen GC et al. Post-diagnostic C-reactive protein and albumin predict survival in Chinese patients with non-small cell lung cancer: a prospective cohort study. Sci. Rep. 9(1), 8143 (2019).
  MedlineGoogle Scholar
• 63. Iivanainen S, Ahvonen J, Knuuttila A, Tiainen S, Koivunen JP. Elevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitors. ESMO Open 4(4), e000531 (2019).
  MedlineGoogle Scholar
• 64. Matsubara T, Takamori S, Haratake N et al. The impact of immune-inflammation-nutritional parameters on the prognosis of non-small cell lung cancer patients treated with atezolizumab. J. Thorac. Dis. 12(4), 1520–1528 (2020).
  MedlineGoogle Scholar
• 65. Dercle L, Ammari S, Champiat S et al. Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapy. Eur. J. Cancer. 65, 33–42 (2016).
  MedlineGoogle Scholar
• 66. Shen W, Chen J, Gantz M, Velasquez G, Punyanitya M, Heymsfield SB. A single MRI slice does not accurately predict visceral and subcutaneous adipose tissue changes during weight loss. Obesity 20(12), 2458–2463 (2012).
  MedlineGoogle Scholar
• 67. Decazes P, Tonnelet D, Vera P, Gardin I. Anthropometer3D: automatic multi-slice segmentation software for the measurement of anthropometric parameters from CT of PET/CT. J. Digit. Imaging 32(2), 241–250 (2019).
  MedlineGoogle Scholar
• 68. Hakimi AA, Furberg H, Zabor EC et al. An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinoma. J. Natl. Cancer Inst. 105(24), 1862–1870 (2013).
  Medline CASGoogle Scholar
• 69. Caan BJ, Meyerhardt JA, Kroenke CH et al. Explaining the obesity paradox: the association between body composition and colorectal cancer survival (C-SCANS study). Cancer Epidemiol. Biomarkers Prev. 26(7), 1008–1015 (2017).
  MedlineGoogle Scholar
• 70. Lam VK, Bentzen SM, Mohindra P et al. Obesity is associated with long-term improved survival in definitively treated locally advanced non-small cell lung cancer (NSCLC). Lung Cancer 104, 52–57 (2017).
  MedlineGoogle Scholar
• 71. McQuade JL, Daniel CR, Hess KR et al. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol. 19(3), 310–322 (2018).
  MedlineGoogle Scholar
• 72. Cortellini A, Bersanelli M, Buti S et al. A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable. J. Immunother. Cancer. 7(1), 57 (2019).
  MedlineGoogle Scholar
• 73. Heidelberger V, Goldwasser F, Kramkimel N et al. Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients. Invest. New Drugs. 35(4), 436–441 (2017).
  MedlineGoogle Scholar
• 74. Conforti F, Pala L, Bagnardi V et al. Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis. Lancet Oncol. 19(6), 737–746 (2018).
  Medline CASGoogle Scholar
• 75. Cortellini A, Tiseo M, Banna GL et al. Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥50%. Cancer Immunol. Immunother. 69(11), 2209–2221 (2020).
  Medline CASGoogle Scholar
• 76. Derosa L, Hellmann MD, Spaziano M et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann. Oncol. 29(6), 1437–1444 (2018).
  Medline CASGoogle Scholar
• 77. Schett A, Rothschild SI, Curioni-Fontecedro A et al. Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors: antibiotics immune checkpoint inhibitors in advanced NSCLC. Cancer Chemother. Pharmacol. 85(1), 121–131 (2020).
  Medline CASGoogle Scholar
• 78. Huang XZ, Gao P, Song YX et al. Antibiotic use and the efficacy of immune checkpoint inhibitors in cancer patients: a pooled analysis of 2740 cancer patients. Oncoimmunology 8(12), e1665973 (2019).
  MedlineGoogle Scholar
• 79. McMillan DC. An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer. Proc. Nutr. Soc. 67(3), 257–262 (2008). • Study on the importance and correlation of the combined management of nutritional and inflammation-related aspects.
  MedlineGoogle Scholar
• 80. Fidler IJ, Poste G. The “seed and soil” hypothesis revisited. Lancet Oncol. 9(8), 808 (2008).
  MedlineGoogle Scholar
• 81. Lutz CT, Quinn LS. Sarcopenia, obesity, and natural killer cell immune senescence in aging: altered cytokine levels as a common mechanism. Aging 4(8), 535–546 (2012).
  Medline CASGoogle Scholar
• 82. Afzali AM, Müntefering T, Wiendl H, Meuth SG, Ruck T. Skeletal muscle cells actively shape (auto)immune responses. Autoimmun. Rev. 17(5), 518–529 (2018).
  Medline CASGoogle Scholar
• 83. Quinn LS. Interleukin-15: a muscle-derived cytokine regulating fat-to-lean body composition. J. Anim. Sci. 86(Suppl. 14), E75–E83 (2008).
  Medline CASGoogle Scholar
• 84. Pesce S, Greppi M, Tabellini G et al. Identification of a subset of human natural killer cells expressing high levels of programmed death 1: a phenotypic and functional characterization. J. Allergy Clin. Immunol. 139(1), 335–346.e3 (2017).
  Medline CASGoogle Scholar
• 85. Deng T, Lyon CJ, Bergin S, Caligiuri MA, Hsueh WA. Obesity, inflammation, and cancer. Annu. Rev. Pathol. 11, 421–449 (2016). • This review summarises several relationships between obesity, inflammation and cancer.
  Medline CASGoogle Scholar
• 86. Wang Z, Aguilar EG, Luna JI et al. Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. Nat. Med. 25(1), 141–151 (2019).
  Medline CASGoogle Scholar